Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
Open Access
- 30 April 2013
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 13 (4), 349-361
- https://doi.org/10.1016/s1473-3099(13)70008-2
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosisAIDS, 2012
- The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapyAIDS, 2012
- Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive studyThe Lancet Infectious Diseases, 2012
- Characteristics and Early Outcomes of Patients With Xpert MTB/RIF-Negative Pulmonary Tuberculosis Diagnosed During Screening Before Antiretroviral TherapyClinical Infectious Diseases, 2012
- Tuberculosis in Antiretroviral Treatment Services in Resource-Limited Settings: Addressing the Challenges of Screening and DiagnosisThe Journal of Infectious Diseases, 2011
- Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyThe Lancet, 2011
- Rapid Molecular Detection of Tuberculosis and Rifampin ResistanceThe New England Journal of Medicine, 2010
- Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence SettingJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Drivers of tuberculosis epidemics: The role of risk factors and social determinantsSocial Science & Medicine (1982), 2009
- Molecular Beacons: Probes that Fluoresce upon HybridizationNature Biotechnology, 1996